证券代码：688716 证券简称：中研股份 公告编号：2025-024 一、监事会会议召开情况 吉林省中研高分子材料股份有限公司（以下简称"公司"）第四届监事会 第五次会议通知于 2025 年 8 月 15 日以专人送达等方式送达全体监事，会议于 会议应出席监事 3 人，实际出席监事 3 人，本次会议的召集、召开和表决程序 符合《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和 国证券法》（以下简称"《证券法》"）《上海证券交易所科创板股票上市规 则》等相关法律、行政法规、规范性文件及《吉林省中研高分子材料股份有限 公司章程》（以下简称"《公司章程》"）《吉林省中研高分子材料股份有限 公司监事会议事规则》等有关规定。 二、监事会会议审议情况 本次会议经全体监事表决，形成决议如下： （一）审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 经审议，监事会认为：公司 2025 年半年度报告及其摘要的编制和审议程序 符合相关法律法规及《公司章程》等内部规章制度的规定，报告真实、准确、 完整地反映了公司的财务状况和经营情况，不存在虚假记载、误导性陈述或重 大遗漏。 吉林省中研高分子材料股份有限 ...

证券代码：688716 证券简称：中研股份 公告编号：2025-023 吉林省中研高分子材料股份有限公司 第四届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 吉林省中研高分子材料股份有限公司（以下简称"公司"）第四届董事会 第五次会议的通知于 2025 年 8 月 15 日以专人送达等方式送达全体董事，会议 于 2025 年 8 月 27 日以现场结合通讯的方式召开。本次会议由董事长谢怀杰先 生主持，会议应出席董事 9 人，实际出席董事 9 人，公司监事列席了本次会议。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》（以下简称 "《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"） 《上海证券交易所科创板股票上市规则》等相关法律、行政法规、规范性文件 及《吉林省中研高分子材料股份有限公司章程》（以下简称"《公司章程》"） 的有关规定。 二、董事会会议审议情况 本次会议经全体董事表决，形成决议如下： （一）审议通过《关于公司<2025 年半年度报告> ...

Core Viewpoint - The company, Jilin Zhongyan High Polymer Materials Co., Ltd., is adjusting the internal investment structure of certain fundraising projects and using its own funds to pay for R&D personnel costs, which will later be replaced with equivalent amounts from the raised funds [1][10]. Fundraising Overview - The company has raised a total of RMB 902.26 million through the issuance of 30,420,000 shares at a price of RMB 29.66 per share, with a net amount of RMB 799.71 million after deducting issuance costs [1][2]. - All raised funds are managed in a dedicated account, with agreements in place between the company, its subsidiaries, and the commercial banks [2]. Project Adjustment Details - The project "Shanghai Carbon Fiber PEEK Composite Material R&D Center" has undergone changes in its implementation subject, location, and total investment amount, which has increased to RMB 110.20 million [3][5]. - The internal investment structure has been adjusted, with construction investment increasing and R&D personnel costs being reduced [5][6]. Reasons for Adjustment - The adjustments are made to enhance R&D capabilities and improve resource allocation without affecting the project's implementation or the interests of shareholders [6][8]. - The company aims to prioritize laboratory construction and equipment procurement due to the urgency of the project [5][6]. Use of Own Funds - The company plans to use its own funds to pay for R&D personnel costs during the project implementation and will replace these amounts with raised funds later [7][8]. - This approach is intended to improve operational efficiency and reduce financial costs while ensuring compliance with relevant regulations [8][9]. Approval Process - The adjustments were approved by the company's board of directors and supervisory board, confirming that the changes do not adversely affect the company's operations or shareholder interests [9][10]. - The company has established operational procedures to ensure the proper management of funds and compliance with regulations [10].